drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00424 | DB00902 | 19 | 104 | [
"DDInter896",
"DDInter1168"
] | Hyoscyamine | Methdilazine | Hyoscyamine is a tropane alkaloid and the levo-isomer of [atropine]. It is commonly extracted from plants in the _Solanaceae_ or nightshade family. Research into the action of hyoscyamine in published literature dates back to 1826. Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimus... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
19,
24,
104
]
],
[
[
19,
24,
13
],
[
13,
24,
104
]
],
[
[
19,
24,
820
],
[
820,
1,
104
]
],
[
[
19,
24,
537
],
[
537,
40,
... | [
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Hyoscyamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazi... |
DB11978 | DB14509 | 124 | 1,399 | [
"DDInter822",
"DDInter1081"
] | Glasdegib | Lithium carbonate | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
124,
24,
1399
]
],
[
[
124,
63,
1374
],
[
1374,
24,
1399
]
],
[
[
124,
64,
609
],
[
609,
24,
1399
]
],
[
[
124,
24,
484
],
[
484,
... | [
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
... | Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Glasdegib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithrom... |
DB06595 | DB09049 | 1,491 | 1,135 | [
"DDInter1214",
"DDInter1261"
] | Midostaurin | Naloxegol | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hem... | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Minor | 0 | [
[
[
1491,
23,
1135
]
],
[
[
1491,
64,
33
],
[
33,
23,
1135
]
],
[
[
1491,
63,
495
],
[
495,
23,
1135
]
],
[
[
1491,
24,
971
],
[
971,
... | [
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone"... | Midostaurin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine and Ezogabine may cause a m... |
DB09420 | DB14509 | 1,074 | 1,399 | [
"DDInter953",
"DDInter1081"
] | Iodide I-123 | Lithium carbonate | Iodide I-123 (as sodium Iodide I-123) is a radioactive isotope of iodine used in nuclear medicine for the diagnostic study of thyroid disease. Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland. After incorporation, a gamma camera is used to detect t... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1074,
24,
1399
]
],
[
[
1074,
63,
1479
],
[
1479,
23,
1399
]
],
[
[
1074,
63,
820
],
[
820,
24,
1399
]
],
[
[
1074,
63,
1527
],
[
1527... | [
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Iodide I-123",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic ... | Iodide I-123 may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Iodide I-123 may cause a moderate interaction that could exacerbate diseases when tak... |
DB01118 | DB11834 | 33 | 1,303 | [
"DDInter76",
"DDInter849"
] | Amiodarone | Guselkumab | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstra... | Moderate | 1 | [
[
[
33,
24,
1303
]
],
[
[
33,
24,
792
],
[
792,
24,
1303
]
],
[
[
33,
63,
58
],
[
58,
24,
1303
]
],
[
[
33,
64,
467
],
[
467,
24,
... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
... | Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefa... |
DB01367 | DB06764 | 1,163 | 1,090 | [
"DDInter1572",
"DDInter1788"
] | Rasagiline | Tetryzoline (ophthalmic) | Rasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases. | Tetryzoline is a member of imidazolines and a carboxamidine. It has a role as a sympathomimetic agent and a nasal decongestant. It is a conjugate base of a tetryzoline(1+). | Moderate | 1 | [
[
[
1163,
24,
1090
]
],
[
[
1163,
24,
144
],
[
144,
63,
1090
]
],
[
[
1163,
63,
688
],
[
688,
24,
1090
]
],
[
[
1163,
64,
222
],
[
222,
... | [
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
]
],
[
[
"Rasagiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
... | Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Rasagiline may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline
Rasagili... |
DB00771 | DB00915 | 262 | 1,170 | [
"DDInter397",
"DDInter60"
] | Clidinium | Amantadine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesi... | Moderate | 1 | [
[
[
262,
24,
1170
]
],
[
[
262,
63,
1219
],
[
1219,
24,
1170
]
],
[
[
262,
24,
832
],
[
832,
24,
1170
]
],
[
[
262,
24,
1376
],
[
1376,
... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amantadine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Amantadine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine and Tripel... |
DB00374 | DB00678 | 1,061 | 240 | [
"DDInter1852",
"DDInter1095"
] | Treprostinil | Losartan | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough simila... | Moderate | 1 | [
[
[
1061,
24,
240
]
],
[
[
1061,
24,
1414
],
[
1414,
1,
240
]
],
[
[
1061,
63,
217
],
[
217,
1,
240
]
],
[
[
1061,
24,
911
],
[
911,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Losartan"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eprosartan"
],
[
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Eprosartan and Eprosartan (Compound) resembles Losartan (Compound)
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Losartan (Compound)
... |
DB08880 | DB09123 | 1,510 | 1,525 | [
"DDInter1771",
"DDInter546"
] | Teriflunomide | Dienogest | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Moderate | 1 | [
[
[
1510,
24,
1525
]
],
[
[
1510,
64,
1064
],
[
1064,
24,
1525
]
],
[
[
1510,
25,
1303
],
[
1303,
63,
1525
]
],
[
[
1510,
24,
1501
],
[
15... | [
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dienogest"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladr... | Teriflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Teriflunomide may lead to a major life threatening interaction when taken with Guselkumab and Guselkumab may cause a moderate... |
DB00432 | DB01030 | 1,083 | 869 | [
"DDInter1868",
"DDInter1835"
] | Trifluridine | Topotecan | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity... | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Moderate | 1 | [
[
[
1083,
24,
869
]
],
[
[
1083,
7,
2903
],
[
2903,
46,
869
]
],
[
[
1083,
7,
5337
],
[
5337,
57,
869
]
],
[
[
1083,
18,
10699
],
[
10699,... | [
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
]
],
[
[
"Trifluridine",
"{u} (Compound) upregulates {v} (Gene)",
"MMP1"
],
[
"MMP1",
"{u} (Gene) is upregulated by {v} (... | Trifluridine (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Topotecan (Compound)
Trifluridine (Compound) upregulates ATP1B1 (Gene) and ATP1B1 (Gene) is downregulated by Topotecan (Compound)
Trifluridine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Topotecan (Compoun... |
DB00065 | DB00242 | 581 | 1,064 | [
"DDInter923",
"DDInter392"
] | Infliximab | Cladribine | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Major | 2 | [
[
[
581,
25,
1064
]
],
[
[
581,
25,
1426
],
[
1426,
64,
1064
]
],
[
[
581,
24,
1525
],
[
1525,
63,
1064
]
],
[
[
581,
25,
869
],
[
869,
... | [
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
]
],
[
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Azacitidine"
],
[
"Azacitidine",
"{u}... | Infliximab may lead to a major life threatening interaction when taken with Azacitidine and Azacitidine may lead to a major life threatening interaction when taken with Cladribine
Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Dienogest and Dienogest may cause a moderate inte... |
DB00431 | DB01209 | 1,503 | 1,359 | [
"DDInter1072",
"DDInter531"
] | Lindane | Dezocine | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due ... | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
1503,
24,
1359
]
],
[
[
1503,
24,
234
],
[
234,
1,
1359
]
],
[
[
1503,
24,
1264
],
[
1264,
24,
1359
]
],
[
[
1503,
24,
1662
],
[
1662,... | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
"Pe... | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate ... |
DB00986 | DB06702 | 1,192 | 573 | [
"DDInter834",
"DDInter731"
] | Glycopyrronium | Fesoterodine | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome. | Moderate | 1 | [
[
[
1192,
24,
573
]
],
[
[
1192,
24,
211
],
[
211,
1,
573
]
],
[
[
1192,
63,
494
],
[
494,
1,
573
]
],
[
[
1192,
6,
2720
],
[
2720,
... | [
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fesoterodine"
]
],
[
[
"Glycopyrronium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
... | Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Fesoterodine (Compound)
Glycopyrronium may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide (Compound) resembles Fesote... |
DB00013 | DB00472 | 1,255 | 758 | [
"DDInter1905",
"DDInter758"
] | Urokinase | Fluoxetine | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies. | Moderate | 1 | [
[
[
1255,
24,
758
]
],
[
[
1255,
24,
109
],
[
109,
40,
758
]
],
[
[
1255,
25,
936
],
[
936,
63,
758
]
],
[
[
1255,
24,
714
],
[
714,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
... | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) resembles Fluoxetine (Compound)
Urokinase may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate disease... |
DB00526 | DB01181 | 1,555 | 1,532 | [
"DDInter1355",
"DDInter906"
] | Oxaliplatin | Ifosfamide | Oxaliplatin is a platinum-based chemotherapy drug in the same family as cisplatin and carboplatin. Compared to cisplatin the two amine groups are replaced by diamino cyclohexane (DACH) group to provide a greater antitumor effect. However, this leads to poorer water solubility, which was compensated by the addition of t... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
1555,
24,
1532
]
],
[
[
1555,
24,
956
],
[
956,
23,
1532
]
],
[
[
1555,
64,
1176
],
[
1176,
23,
1532
]
],
[
[
1555,
25,
945
],
[
945,
... | [
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
[... | Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide
Oxaliplatin may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin may ... |
DB00631 | DB01362 | 372 | 497 | [
"DDInter405",
"DDInter960"
] | Clofarabine | Iohexol | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
372,
25,
497
]
],
[
[
372,
25,
258
],
[
258,
40,
497
]
],
[
[
372,
21,
28681
],
[
28681,
60,
497
]
],
[
[
372,
63,
1523
],
[
1523,
... | [
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Com... | Clofarabine may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Clofarabine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Clofarabine may cause a moderate interaction that c... |
DB00213 | DB01232 | 837 | 1,327 | [
"DDInter1388",
"DDInter1640"
] | Pantoprazole | Saquinavir | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zolling... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
837,
24,
1327
]
],
[
[
837,
25,
798
],
[
798,
40,
1327
]
],
[
[
837,
24,
215
],
[
215,
40,
1327
]
],
[
[
837,
6,
15333
],
[
15333,
... | [
[
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Pantoprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nelfinavir"
],
[
"Nelfin... | Pantoprazole may lead to a major life threatening interaction when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir (Compound) resembles Saquinavir (Compound)
Pantoprazole ... |
DB01576 | DB09080 | 93 | 144 | [
"DDInter526",
"DDInter1331"
] | Dextroamphetamine | Olodaterol | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
93,
24,
144
]
],
[
[
93,
74,
1445
],
[
1445,
24,
144
]
],
[
[
93,
1,
80
],
[
80,
24,
144
]
],
[
[
93,
64,
121
],
[
121,
24,
... | [
[
[
"Dextroamphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate disease... | Dextroamphetamine (Compound) resembles Pseudoephedrine (Compound) and Dextroamphetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dextroamphetamine (Compou... |
DB01041 | DB09276 | 770 | 381 | [
"DDInter1789",
"DDInter1682"
] | Thalidomide | Sodium aurothiomalate | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Sodium aurothiomalate is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Gold Sodium Thiomalate is supplied as a solution for intramuscular injection containing 50 mg of Gold Sodium Thiomalate per mL. It is most effective in active progressive rheumatoid arthritis and of little or no valu... | Moderate | 1 | [
[
[
770,
24,
381
]
],
[
[
770,
24,
1683
],
[
1683,
24,
381
]
],
[
[
770,
63,
491
],
[
491,
24,
381
]
],
[
[
770,
64,
63
],
[
63,
24,... | [
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium aurothiomalate"
]
],
[
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
... | Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Sodium aurothiomalate
Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Pegint... |
DB01068 | DB14723 | 1,565 | 159 | [
"DDInter411",
"DDInter1026"
] | Clonazepam | Larotrectinib | A benzodiazepine used to treat various seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop.[FDA Label][L5572,F3763,F3787,F3796] The agent has also been indicated for treating panic disorder.[FDA Label][A175438,L5572,F3763,F3787,F3796] The mechan... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
1565,
24,
159
]
],
[
[
1565,
24,
222
],
[
222,
23,
159
]
],
[
[
1565,
24,
98
],
[
98,
24,
159
]
],
[
[
1565,
1,
481
],
[
481,
24... | [
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
... | Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somat... |
DB00290 | DB01320 | 329 | 651 | [
"DDInter219",
"DDInter783"
] | Bleomycin | Fosphenytoin | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Moderate | 1 | [
[
[
329,
24,
651
]
],
[
[
329,
63,
362
],
[
362,
1,
651
]
],
[
[
329,
21,
28684
],
[
28684,
60,
651
]
],
[
[
329,
24,
147
],
[
147,
... | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
... | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Bleomycin (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Fosphenytoin (Compound)
Bleomycin may cause a moderate inter... |
DB00656 | DB08899 | 827 | 129 | [
"DDInter1851",
"DDInter649"
] | Trazodone | Enzalutamide | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
827,
24,
129
]
],
[
[
827,
24,
918
],
[
918,
1,
129
]
],
[
[
827,
6,
8374
],
[
8374,
45,
129
]
],
[
[
827,
21,
28703
],
[
28703,
... | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
... | Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Trazodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Trazodone (Compound) causes Pruritus (Side Effect) and Pruri... |
DB00719 | DB01200 | 1,219 | 469 | [
"DDInter149",
"DDInter243"
] | Azatadine | Bromocriptine | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. Bromocriptine is also indicated for the management of signs and symptoms of Parkinsonian Syndrome, as well as t... | Moderate | 1 | [
[
[
1219,
24,
469
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
469
]
],
[
[
1219,
24,
401
],
[
401,
24,
469
]
],
[
[
1219,
63,
701
],
[
701,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bromocriptine"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bromocriptine (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Bromocriptine
Azatadine ... |
DB00916 | DB01076 | 112 | 700 | [
"DDInter1202",
"DDInter133"
] | Metronidazole | Atorvastatin | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competi... | Moderate | 1 | [
[
[
112,
24,
700
]
],
[
[
112,
24,
788
],
[
788,
1,
700
]
],
[
[
112,
6,
6017
],
[
6017,
45,
700
]
],
[
[
112,
64,
126
],
[
126,
23,... | [
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atorvastatin"
]
],
[
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
]... | Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin (Compound) resembles Atorvastatin (Compound)
Metronidazole (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Atorvastatin (Compound)
Metronidazole may lead to a major life threatening i... |
DB00655 | DB08882 | 559 | 1,281 | [
"DDInter682",
"DDInter1070"
] | Estrone | Linagliptin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes . Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin ... | Moderate | 1 | [
[
[
559,
24,
1281
]
],
[
[
559,
24,
1002
],
[
1002,
1,
1281
]
],
[
[
559,
6,
8374
],
[
8374,
45,
1281
]
],
[
[
559,
21,
29081
],
[
29081,
... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
]
],
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
"... | Estrone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Estrone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Estrone (Compound) causes Angioedema (Side Effect) and Angioedema (Sid... |
DB00563 | DB06688 | 663 | 1,430 | [
"DDInter1174",
"DDInter1677"
] | Methotrexate | Sipuleucel-T | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
663,
24,
1430
]
],
[
[
663,
24,
175
],
[
175,
24,
1430
]
],
[
[
663,
25,
676
],
[
676,
63,
1430
]
],
[
[
663,
63,
589
],
[
589,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Methotrexate may lead to a major life threatening interaction when taken with Upadacitinib and Upadaci... |
DB00444 | DB11932 | 63 | 327 | [
"DDInter1765",
"DDInter3"
] | Teniposide | Abametapir (topical) | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | Abametapir is a member of bipyridines. | Moderate | 1 | [
[
[
63,
24,
327
]
],
[
[
63,
63,
168
],
[
168,
24,
327
]
],
[
[
63,
24,
283
],
[
283,
63,
327
]
],
[
[
63,
24,
309
],
[
309,
24,
... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abametapir"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Abametapir
Teniposide... |
DB00624 | DB09122 | 1,561 | 1,613 | [
"DDInter1775",
"DDInter1409"
] | Testosterone | Peginterferon beta-1a | Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual charact... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
1561,
24,
1613
]
],
[
[
1561,
63,
600
],
[
600,
24,
1613
]
],
[
[
1561,
24,
267
],
[
267,
24,
1613
]
],
[
[
1561,
24,
351
],
[
351,
... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Nalt... |
DB00500 | DB01099 | 24 | 1,272 | [
"DDInter1831",
"DDInter744"
] | Tolmetin | Flucytosine | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | A fluorinated cytosine analog that is used as an antifungal agent. | Moderate | 1 | [
[
[
24,
24,
1272
]
],
[
[
24,
21,
28658
],
[
28658,
60,
1272
]
],
[
[
24,
24,
1448
],
[
1448,
24,
1272
]
],
[
[
24,
63,
599
],
[
599,
... | [
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
]
],
[
[
"Tolmetin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by... | Tolmetin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Flucytosine (Compound)
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flucytos... |
DB00519 | DB08938 | 1,638 | 1,384 | [
"DDInter1843",
"DDInter1112"
] | Trandolapril | Magaldrate | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiote... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
1638,
23,
1384
]
],
[
[
1638,
24,
167
],
[
167,
23,
1384
]
],
[
[
1638,
1,
610
],
[
610,
23,
1384
]
],
[
[
1638,
63,
251
],
[
251,
... | [
[
[
"Trandolapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Trandolapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
... | Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Trandolapril (Compound) resembles Enalapril (Compound) and Enalapril may cause a minor interaction that ... |
DB00687 | DB00745 | 870 | 307 | [
"DDInter747",
"DDInter1236"
] | Fludrocortisone | Modafinil | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
870,
23,
307
]
],
[
[
870,
25,
1301
],
[
1301,
40,
307
]
],
[
[
870,
63,
362
],
[
362,
40,
307
]
],
[
[
870,
24,
651
],
[
651,
4... | [
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Fludrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
... | Fludrocortisone may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Modafinil (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Modafinil (Compo... |
DB00427 | DB00652 | 1,233 | 234 | [
"DDInter1879",
"DDInter1421"
] | Triprolidine | Pentazocine | First generation histamine H1 antagonist used in allergic rhinitis; asthma; and urticaria. It is a component of cough and cold medicines. It may cause drowsiness. | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Moderate | 1 | [
[
[
1233,
24,
234
]
],
[
[
1233,
24,
1359
],
[
1359,
40,
234
]
],
[
[
1233,
24,
537
],
[
537,
63,
234
]
],
[
[
1233,
63,
999
],
[
999,
... | [
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
]
],
[
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
],
[... | Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Dezocine and Dezocine (Compound) resembles Pentazocine (Compound)
Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could ... |
DB00346 | DB08907 | 472 | 1,344 | [
"DDInter44",
"DDInter280"
] | Alfuzosin | Canagliflozin | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 f... | Moderate | 1 | [
[
[
472,
24,
1344
]
],
[
[
472,
24,
549
],
[
549,
1,
1344
]
],
[
[
472,
6,
8374
],
[
8374,
45,
1344
]
],
[
[
472,
21,
28646
],
[
28646,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]
],
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
... | Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin (Compound) resembles Canagliflozin (Compound)
Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Canagliflozin (Compound)
Alfuzosin (Compound) causes Unspecified disorder of skin... |
DB00470 | DB00745 | 530 | 307 | [
"DDInter601",
"DDInter1236"
] | Dronabinol | Modafinil | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron ac... | Minor | 0 | [
[
[
530,
23,
307
]
],
[
[
530,
24,
704
],
[
704,
40,
307
]
],
[
[
530,
25,
1301
],
[
1301,
40,
307
]
],
[
[
530,
63,
362
],
[
362,
4... | [
[
[
"Dronabinol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
]
],
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fentanyl"
],
[
"... | Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Fentanyl and Fentanyl (Compound) resembles Modafinil (Compound)
Dronabinol may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Modafinil (Compound)
Dronabi... |
DB01097 | DB01284 | 1,377 | 1,042 | [
"DDInter1033",
"DDInter1782"
] | Leflunomide | Tetracosactide | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticoste... | Major | 2 | [
[
[
1377,
25,
1042
]
],
[
[
1377,
25,
1683
],
[
1683,
63,
1042
]
],
[
[
1377,
64,
1561
],
[
1561,
24,
1042
]
],
[
[
1377,
63,
1144
],
[
11... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
... | Leflunomide may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Leflunomide may lead to a major life threatening interaction when taken with Testosterone and Testosterone may cause a m... |
DB00539 | DB01236 | 11 | 679 | [
"DDInter1837",
"DDInter1664"
] | Toremifene | Sevoflurane | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has est... | Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 199... | Major | 2 | [
[
[
11,
25,
679
]
],
[
[
11,
25,
1262
],
[
1262,
40,
679
]
],
[
[
11,
6,
8374
],
[
8374,
45,
679
]
],
[
[
11,
21,
29122
],
[
29122,
... | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sevoflurane"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perflutren"
],
[
"Perflutren",
"{u} ... | Toremifene may lead to a major life threatening interaction when taken with Perflutren and Perflutren (Compound) resembles Sevoflurane (Compound)
Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sevoflurane (Compound)
Toremifene (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal... |
DB01224 | DB05812 | 623 | 1,374 | [
"DDInter1553",
"DDInter8"
] | Quetiapine | Abiraterone | Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable opti... | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Moderate | 1 | [
[
[
623,
24,
1374
]
],
[
[
623,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
623,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
623,
62,
112
],
[
112,... | [
[
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Quetiapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)"... | Quetiapine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Quetiapine (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Quetiapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole... |
DB00563 | DB01406 | 663 | 984 | [
"DDInter1174",
"DDInter472"
] | Methotrexate | Danazol | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
663,
24,
984
]
],
[
[
663,
24,
1546
],
[
1546,
1,
984
]
],
[
[
663,
24,
1026
],
[
1026,
40,
984
]
],
[
[
663,
18,
3833
],
[
3833,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Danazol (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone and Oxandrolone (Compound) resembles Dan... |
DB01263 | DB08895 | 859 | 976 | [
"DDInter1494",
"DDInter1825"
] | Posaconazole | Tofacitinib | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
859,
25,
976
]
],
[
[
859,
63,
660
],
[
660,
24,
976
]
],
[
[
859,
25,
214
],
[
214,
63,
976
]
],
[
[
859,
25,
868
],
[
868,
24,... | [
[
[
"Posaconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Posaconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Eso... | Posaconazole may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Posaconazole may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatin... |
DB01254 | DB06448 | 1,213 | 171 | [
"DDInter484",
"DDInter1087"
] | Dasatinib | Lonafarnib | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the break... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
1213,
25,
171
]
],
[
[
1213,
63,
222
],
[
222,
23,
171
]
],
[
[
1213,
63,
1601
],
[
1601,
24,
171
]
],
[
[
1213,
62,
112
],
[
112,
... | [
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine... | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Lonafarnib
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Loratadine and Loratadi... |
DB00999 | DB11827 | 504 | 433 | [
"DDInter883",
"DDInter669"
] | Hydrochlorothiazide | Ertugliflozin | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
504,
24,
433
]
],
[
[
504,
24,
959
],
[
959,
24,
433
]
],
[
[
504,
63,
251
],
[
251,
24,
433
]
],
[
[
504,
1,
1577
],
[
1577,
24... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipiz... | Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Be... |
DB00836 | DB00889 | 543 | 1,133 | [
"DDInter1088",
"DDInter840"
] | Loperamide | Granisetron | Loperamide is an anti-diarrheal agent that is available as various over-the-counter products for treating diarrhea. The drug was first synthesized in 1969 and used medically in 1976. It is a highly lipophilic synthetic phenylpiperidine opioid that is structurally similar to opiate receptor agonists such as [diphenoxyla... | A serotonin receptor (5HT-3 selective) antagonist that has been used as an antiemetic and antinauseant for cancer chemotherapy patients. | Moderate | 1 | [
[
[
543,
24,
1133
]
],
[
[
543,
63,
19
],
[
19,
40,
1133
]
],
[
[
543,
63,
85
],
[
85,
1,
1133
]
],
[
[
543,
6,
8374
],
[
8374,
45,
... | [
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
]
],
[
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine (Compound) resembles Granisetron (Compound)
Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine (Compound) resembles Granisetron (Compound)
... |
DB00035 | DB06212 | 1,314 | 165 | [
"DDInter507",
"DDInter1833"
] | Desmopressin | Tolvaptan | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release... | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
1314,
24,
165
]
],
[
[
1314,
6,
9906
],
[
9906,
45,
165
]
],
[
[
1314,
21,
28789
],
[
28789,
60,
165
]
],
[
[
1314,
24,
147
],
[
147,
... | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Desmopressin",
"{u} (Compound) binds {v} (Gene)",
"AVPR1A"
],
[
"AVPR1A",
"{u} (Gene) is bound by {v} (Compound... | Desmopressin (Compound) binds AVPR1A (Gene) and AVPR1A (Gene) is bound by Tolvaptan (Compound)
Desmopressin (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Tolvaptan (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when ta... |
DB00495 | DB00773 | 139 | 896 | [
"DDInter1961",
"DDInter702"
] | Zidovudine | Etoposide | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
139,
24,
896
]
],
[
[
139,
6,
3486
],
[
3486,
45,
896
]
],
[
[
139,
7,
9681
],
[
9681,
57,
896
]
],
[
[
139,
21,
32164
],
[
32164,
... | [
[
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Zidovudine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
... | Zidovudine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Etoposide (Compound)
Zidovudine (Compound) upregulates THAP11 (Gene) and THAP11 (Gene) is downregulated by Etoposide (Compound)
Zidovudine (Compound) causes Nail pigmentation (Side Effect) and Nail pigmentation (Side Effect) is caused by Etoposide ... |
DB00593 | DB01611 | 1,464 | 1,487 | [
"DDInter695",
"DDInter893"
] | Ethosuximide | Hydroxychloroquine | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Moderate | 1 | [
[
[
1464,
24,
1487
]
],
[
[
1464,
21,
28658
],
[
28658,
60,
1487
]
],
[
[
1464,
24,
723
],
[
723,
24,
1487
]
],
[
[
1464,
24,
980
],
[
980... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Ethosuximide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effec... | Ethosuximide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Hydroxychloroquine (Compound)
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00176 | DB00945 | 529 | 1,479 | [
"DDInter770",
"DDInter20"
] | Fluvoxamine | Acetylsalicylic acid | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database ... | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
529,
24,
1479
]
],
[
[
529,
6,
10215
],
[
10215,
45,
1479
]
],
[
[
529,
21,
28931
],
[
28931,
60,
1479
]
],
[
[
529,
24,
837
],
[
837,... | [
[
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Fluvoxamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v... | Fluvoxamine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Acetylsalicylic acid (Compound)
Fluvoxamine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Acetylsalicylic acid (Compound)
Fluvoxamine may cause a moderate interaction that could exacerbate diseases when t... |
DB00261 | DB00557 | 702 | 252 | [
"DDInter93",
"DDInter895"
] | Anagrelide | Hydroxyzine | Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms. It is an oral imidazoquinazoline that was first approved for use in the US in 1997. It appears to carry a better response rate than other thrombocythe... | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Major | 2 | [
[
[
702,
25,
252
]
],
[
[
702,
25,
1630
],
[
1630,
1,
252
]
],
[
[
702,
25,
623
],
[
623,
40,
252
]
],
[
[
702,
21,
28691
],
[
28691,
... | [
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxyzine"
]
],
[
[
"Anagrelide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"... | Anagrelide may lead to a major life threatening interaction when taken with Perphenazine and Perphenazine (Compound) resembles Hydroxyzine (Compound)
Anagrelide may lead to a major life threatening interaction when taken with Quetiapine and Quetiapine (Compound) resembles Hydroxyzine (Compound)
Anagrelide (Compound) ca... |
DB00964 | DB11130 | 1,617 | 407 | [
"DDInter110",
"DDInter1344"
] | Apraclonidine | Opium | Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist. | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Moderate | 1 | [
[
[
1617,
24,
407
]
],
[
[
1617,
63,
662
],
[
662,
24,
407
]
],
[
[
1617,
1,
876
],
[
876,
24,
407
]
],
[
[
1617,
24,
849
],
[
849,
... | [
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
]
],
[
[
"Apraclonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
... | Apraclonidine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Opium
Apraclonidine (Compound) resembles Tizanidine (Compound) and Tizanidine may cause a moderate interaction tha... |
DB00169 | DB09104 | 386 | 286 | [
"DDInter367",
"DDInter1118"
] | Cholecalciferol | Magnesium hydroxide | Vitamin D, in general, is a secosteroid generated in the skin when 7-dehydrocholesterol located there interacts with ultraviolet irradiation - like that commonly found in sunlight. Both the endogenous form of vitamin D (that results from 7-dehydrocholesterol transformation), vitamin D3 (cholecalciferol), and the plant-... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
386,
24,
286
]
],
[
[
386,
24,
1482
],
[
1482,
23,
286
]
],
[
[
386,
23,
752
],
[
752,
23,
286
]
],
[
[
386,
24,
362
],
[
362,
2... | [
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Cholecalciferol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxi... | Cholecalciferol may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Cholecalciferol may cause a minor interaction that can limit clinical effects when taken with Cimetidi... |
DB00405 | DB09034 | 128 | 1,313 | [
"DDInter517",
"DDInter1733"
] | Dexbrompheniramine | Suvorexant | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Moderate | 1 | [
[
[
128,
24,
1313
]
],
[
[
128,
24,
649
],
[
649,
24,
1313
]
],
[
[
128,
63,
701
],
[
701,
24,
1313
]
],
[
[
128,
74,
1594
],
[
1594,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Suvorexant"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol and Clofedanol may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Clema... |
DB00491 | DB00668 | 127 | 874 | [
"DDInter1217",
"DDInter652"
] | Miglitol | Epinephrine | Miglitol inhibits the breakdown complex carbohydrates into glucose. It is primarily used in diabetes mellitus type 2 for establishing greater glycemic control by preventing the digestion of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be absorbed by the bod... | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been avail... | Moderate | 1 | [
[
[
127,
24,
874
]
],
[
[
127,
63,
1636
],
[
1636,
1,
874
]
],
[
[
127,
24,
688
],
[
688,
63,
874
]
],
[
[
127,
24,
817
],
[
817,
1,... | [
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
]
],
[
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
... | Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound)
Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that co... |
DB00781 | DB01276 | 1,481 | 123 | [
"DDInter1489",
"DDInter706"
] | Polymyxin B | Exenatide | Polymyxin B was discovered in the 1940s. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1481,
24,
123
]
],
[
[
1481,
1,
966
],
[
966,
24,
123
]
],
[
[
1481,
25,
1381
],
[
1381,
63,
123
]
],
[
[
1481,
25,
361
],
[
361,
... | [
[
[
"Polymyxin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Polymyxin B",
"{u} (Compound) resembles {v} (Compound)",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a modera... | Polymyxin B (Compound) resembles Octreotide (Compound) and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Exenatide
Polymyxin B may lead to a major life threatening interaction when taken with Plazomicin and Plazomicin may cause a moderate interaction that could exacerbate di... |
DB00454 | DB00771 | 1,349 | 262 | [
"DDInter1150",
"DDInter397"
] | Meperidine | Clidinium | A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration. | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | Moderate | 1 | [
[
[
1349,
24,
262
]
],
[
[
1349,
24,
1511
],
[
1511,
63,
262
]
],
[
[
1349,
40,
1688
],
[
1688,
1,
262
]
],
[
[
1349,
63,
19
],
[
19,
... | [
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clidinium"
]
],
[
[
"Meperidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
... | Meperidine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Clidinium
Meperidine (Compound) resembles Diphenoxylate (Compound) and Diphenoxylate (Compound) resembles Clidinium (Comp... |
DB00041 | DB00773 | 1,648 | 896 | [
"DDInter38",
"DDInter702"
] | Aldesleukin | Etoposide | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Moderate | 1 | [
[
[
1648,
24,
896
]
],
[
[
1648,
23,
945
],
[
945,
62,
896
]
],
[
[
1648,
23,
1299
],
[
1299,
23,
896
]
],
[
[
1648,
25,
147
],
[
147,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Aldesleukin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
... | Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trov... |
DB00222 | DB12015 | 245 | 1,033 | [
"DDInter825",
"DDInter53"
] | Glimepiride | Alpelisib | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in acco... | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
245,
24,
1033
]
],
[
[
245,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
245,
24,
1385
],
[
1385,
63,
1033
]
],
[
[
245,
23,
1051
],
[
1051,
... | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
... | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Semagl... |
DB00877 | DB11560 | 629 | 1,678 | [
"DDInter1678",
"DDInter1038"
] | Sirolimus | Lesinurad | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter assoc... | Moderate | 1 | [
[
[
629,
24,
1678
]
],
[
[
629,
63,
79
],
[
79,
24,
1678
]
],
[
[
629,
25,
913
],
[
913,
63,
1678
]
],
[
[
629,
24,
1491
],
[
1491,
... | [
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Sirolimus may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a m... |
DB00308 | DB09268 | 347 | 1,662 | [
"DDInter901",
"DDInter1464"
] | Ibutilide | Picosulfuric acid | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Major | 2 | [
[
[
347,
25,
1662
]
],
[
[
347,
25,
484
],
[
484,
63,
1662
]
],
[
[
347,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
347,
24,
770
],
[
770,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
... | Ibutilide may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Ibutilide may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a mo... |
DB00370 | DB08899 | 1,251 | 129 | [
"DDInter1230",
"DDInter649"
] | Mirtazapine | Enzalutamide | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
1251,
24,
129
]
],
[
[
1251,
24,
918
],
[
918,
1,
129
]
],
[
[
1251,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1251,
21,
28703
],
[
28703,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide (Compound) resembles Enzalutamide (Compound)
Mirtazapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Mirtazapine (Compound) causes Pruritus (Side Effect) and... |
DB00586 | DB01124 | 1,512 | 1,411 | [
"DDInter537",
"DDInter1828"
] | Diclofenac | Tolbutamide | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release... | Moderate | 1 | [
[
[
1512,
24,
1411
]
],
[
[
1512,
24,
959
],
[
959,
40,
1411
]
],
[
[
1512,
23,
824
],
[
824,
24,
1411
]
],
[
[
1512,
63,
245
],
[
245,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Diclofenac may cause a minor interaction that can limit clinical effects when taken with Probenecid and Probenecid may cause a moderate interaction that could ex... |
DB00902 | DB00980 | 104 | 969 | [
"DDInter1168",
"DDInter1564"
] | Methdilazine | Ramelteon | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
104,
24,
969
]
],
[
[
104,
63,
100
],
[
100,
24,
969
]
],
[
[
104,
24,
1376
],
[
1376,
63,
969
]
],
[
[
104,
40,
820
],
[
820,
6... | [
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
],
... | Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Diphenhy... |
DB01166 | DB01406 | 477 | 984 | [
"DDInter379",
"DDInter472"
] | Cilostazol | Danazol | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders. | Moderate | 1 | [
[
[
477,
24,
984
]
],
[
[
477,
6,
8374
],
[
8374,
45,
984
]
],
[
[
477,
21,
28906
],
[
28906,
60,
984
]
],
[
[
477,
63,
222
],
[
222,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
]
],
[
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Cilostazol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Danazol (Compound)
Cilostazol (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Danazol (Compound)
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine a... |
DB00039 | DB02546 | 1,253 | 137 | [
"DDInter1380",
"DDInter1947"
] | Palifermin | Vorinostat | Palifermin is a recombinant human keratinocyte growth factor (KGF). It is 140 residues long, and is produced using E. coli. Palifermin was granted FDA approval on 15 December 2004. | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Moderate | 1 | [
[
[
1253,
24,
137
]
],
[
[
1253,
24,
770
],
[
770,
25,
137
]
],
[
[
1253,
24,
1077
],
[
1077,
24,
384
],
[
384,
63,
137
]
],
[
[
1253,
... | [
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vorinostat"
]
],
[
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
... | Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Vorinostat
Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat and Belinostat may caus... |
DB00444 | DB00900 | 63 | 45 | [
"DDInter1765",
"DDInter544"
] | Teniposide | Didanosine | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells ... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
63,
24,
45
]
],
[
[
63,
7,
4456
],
[
4456,
46,
45
]
],
[
[
63,
18,
7212
],
[
7212,
57,
45
]
],
[
[
63,
21,
28709
],
[
28709,
60,... | [
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Teniposide",
"{u} (Compound) upregulates {v} (Gene)",
"NOTCH1"
],
[
"NOTCH1",
"{u} (Gene) is upregulated by {v} ... | Teniposide (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Didanosine (Compound)
Teniposide (Compound) downregulates HMG20B (Gene) and HMG20B (Gene) is downregulated by Didanosine (Compound)
Teniposide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is ca... |
DB01166 | DB09020 | 477 | 28 | [
"DDInter379",
"DDInter212"
] | Cilostazol | Bisacodyl | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Bisacodyl, a diphenylmethane derivative, is a commonly used over the counter stimulant laxative for occasional constipation.[A233300,L13362] Both bisacodyl and [picosulfate] are metabolized to the same active metabolite bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM).[A233290,A233300,A207700] Bisacodyl was patented on 2... | Moderate | 1 | [
[
[
477,
24,
28
]
],
[
[
477,
18,
6164
],
[
6164,
46,
28
]
],
[
[
477,
7,
4450
],
[
4450,
46,
28
]
],
[
[
477,
18,
5587
],
[
5587,
5... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
]
],
[
[
"Cilostazol",
"{u} (Compound) downregulates {v} (Gene)",
"UFM1"
],
[
"UFM1",
"{u} (Gene) is upregulated by {v} (Co... | Cilostazol (Compound) downregulates UFM1 (Gene) and UFM1 (Gene) is upregulated by Bisacodyl (Compound)
Cilostazol (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Bisacodyl (Compound)
Cilostazol (Compound) downregulates SCAND1 (Gene) and SCAND1 (Gene) is downregulated by Bisacodyl (Compound)
Cilosta... |
DB09074 | DB14568 | 1,362 | 982 | [
"DDInter1327",
"DDInter1000"
] | Olaparib | Ivosidenib | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Moderate | 1 | [
[
[
1362,
24,
982
]
],
[
[
1362,
63,
168
],
[
168,
23,
982
]
],
[
[
1362,
64,
976
],
[
976,
24,
982
]
],
[
[
1362,
63,
628
],
[
628,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Olaparib may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a mo... |
DB01105 | DB08896 | 222 | 292 | [
"DDInter1665",
"DDInter1576"
] | Sibutramine | Regorafenib | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Moderate | 1 | [
[
[
222,
24,
292
]
],
[
[
222,
6,
8374
],
[
8374,
45,
292
]
],
[
[
222,
21,
28890
],
[
28890,
60,
292
]
],
[
[
222,
24,
549
],
[
549,
... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)
Sibutramine (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Sibutramine may cause a moderate interaction that could exacerbate diseases when t... |
DB00182 | DB06704 | 80 | 247 | [
"DDInter84",
"DDInter951"
] | Amphetamine | Iobenguane (I-123) | Amphetamine, a compound discovered over 100 years ago, is one of the more restricted controlled drugs. It was previously used for a large variety of conditions and this changed until this point where its use is highly restricted. Amphetamine, with the chemical formula alpha-methylphenethylamine, was discovered in 1910 ... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
80,
37,
247
]
],
[
[
80,
6,
7390
],
[
7390,
45,
247
]
],
[
[
80,
21,
28787
],
[
28787,
60,
247
]
],
[
[
80,
24,
820
],
[
820,
24... | [
[
[
"Amphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Amphetamine",
"{u} (Compound) binds {v} (Gene)",
"SLC6... | Amphetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Amphetamine may lead to a major life threatening interaction when taken with Iobenguane
Amphetamine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Amphetamine (Compound) causes ... |
DB00563 | DB09291 | 663 | 741 | [
"DDInter1174",
"DDInter1615"
] | Methotrexate | Rolapitant | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Moderate | 1 | [
[
[
663,
24,
741
]
],
[
[
663,
24,
159
],
[
159,
63,
741
]
],
[
[
663,
24,
1496
],
[
1496,
24,
741
]
],
[
[
663,
63,
1252
],
[
1252,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rolapitant"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib ... |
DB00197 | DB12015 | 1,324 | 1,033 | [
"DDInter1881",
"DDInter53"
] | Troglitazone | Alpelisib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
1324,
24,
1033
]
],
[
[
1324,
24,
1135
],
[
1135,
23,
1033
]
],
[
[
1324,
24,
1254
],
[
1254,
24,
1033
]
],
[
[
1324,
25,
1510
],
[
15... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
... | Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Alpelisib
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and ... |
DB01255 | DB06603 | 633 | 39 | [
"DDInter1078",
"DDInter1387"
] | Lisdexamfetamine | Panobinostat | Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved... | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
633,
25,
39
]
],
[
[
633,
62,
112
],
[
112,
23,
39
]
],
[
[
633,
63,
506
],
[
506,
24,
39
]
],
[
[
633,
24,
720
],
[
720,
63,
... | [
[
[
"Lisdexamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Lisdexamfetamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Dextr... |
DB01175 | DB06788 | 318 | 1,616 | [
"DDInter672",
"DDInter864"
] | Escitalopram | Histrelin | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Major | 2 | [
[
[
318,
25,
1616
]
],
[
[
318,
62,
112
],
[
112,
23,
1616
]
],
[
[
318,
25,
1342
],
[
1342,
24,
1616
]
],
[
[
318,
63,
1179
],
[
1179,
... | [
[
[
"Escitalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Histrelin"
]
],
[
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metron... | Escitalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Escitalopram may lead to a major life threatening interaction when taken with Romidepsin and Romidepsin may c... |
DB00570 | DB06636 | 147 | 1,623 | [
"DDInter1936",
"DDInter980"
] | Vinblastine | Isavuconazonium | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
147,
24,
1623
]
],
[
[
147,
24,
1419
],
[
1419,
24,
1623
]
],
[
[
147,
24,
1593
],
[
1593,
63,
1623
]
],
[
[
147,
63,
450
],
[
450,
... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
... | Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Cri... |
DB00081 | DB09054 | 273 | 384 | [
"DDInter1838",
"DDInter905"
] | Tositumomab | Idelalisib | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination wi... | Moderate | 1 | [
[
[
273,
24,
384
]
],
[
[
273,
24,
222
],
[
222,
23,
384
]
],
[
[
273,
25,
1618
],
[
1618,
24,
384
]
],
[
[
273,
24,
58
],
[
58,
24,... | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[... | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Tositumomab may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may ... |
DB00349 | DB09280 | 902 | 1,604 | [
"DDInter401",
"DDInter1101"
] | Clobazam | Lumacaftor | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike old... | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Con... | Moderate | 1 | [
[
[
902,
24,
1604
]
],
[
[
902,
24,
593
],
[
593,
24,
1604
]
],
[
[
902,
40,
1237
],
[
1237,
24,
1604
]
],
[
[
902,
24,
629
],
[
629,
... | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumacaftor"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"... | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Lumacaftor
Clobazam (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could e... |
DB00607 | DB08881 | 1,249 | 868 | [
"DDInter1256",
"DDInter1925"
] | Nafcillin | Vemurafenib | A semi-synthetic antibiotic related to penicillin, Naficillin is a narrow-spectrum beta-lactam antibiotic drug. It is a beta-lactamase-resistant penicillin that is indicated for the treatment of Staphylococcal infections caused by strains that are resistant to other penicillins, except those caused by MRSA. It may be u... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1249,
24,
868
]
],
[
[
1249,
6,
8374
],
[
8374,
45,
868
]
],
[
[
1249,
7,
3422
],
[
3422,
46,
868
]
],
[
[
1249,
21,
29015
],
[
29015,... | [
[
[
"Nafcillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Nafcillin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Nafcillin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Nafcillin (Compound) upregulates SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)
Nafcillin (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
... |
DB00056 | DB08908 | 816 | 713 | [
"DDInter814",
"DDInter564"
] | Gemtuzumab ozogamicin | Dimethyl fumarate | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MM... | Moderate | 1 | [
[
[
816,
24,
713
]
],
[
[
816,
24,
996
],
[
996,
24,
713
]
],
[
[
816,
24,
270
],
[
270,
63,
713
]
],
[
[
816,
63,
1184
],
[
1184,
2... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when t... |
DB03404 | DB12500 | 765 | 283 | [
"DDInter855",
"DDInter714"
] | Hemin | Fedratinib | Hemin (trade name Panhematin) is an iron-containing porphyrin. More specifically, it is protoporphyrin IX containing a ferric iron ion (heme B) with a chloride ligand. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Moderate | 1 | [
[
[
765,
24,
283
]
],
[
[
765,
63,
885
],
[
885,
24,
283
]
],
[
[
765,
25,
192
],
[
192,
24,
283
]
],
[
[
765,
24,
1618
],
[
1618,
2... | [
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Hemin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epo... | Hemin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Hemin may lead to a major life threatening interaction when taken with Esterified estrogens and Esterified estrog... |
DB06448 | DB08912 | 171 | 1,040 | [
"DDInter1087",
"DDInter462"
] | Lonafarnib | Dabrafenib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib... | Major | 2 | [
[
[
171,
25,
1040
]
],
[
[
171,
63,
168
],
[
168,
23,
1040
]
],
[
[
171,
64,
478
],
[
478,
24,
1040
]
],
[
[
171,
24,
466
],
[
466,
... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Lonafarnib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a mo... |
DB00844 | DB01191 | 314 | 1,039 | [
"DDInter1257",
"DDInter518"
] | Nalbuphine | Dexfenfluramine | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
314,
24,
1039
]
],
[
[
314,
24,
578
],
[
578,
63,
1039
]
],
[
[
314,
1,
828
],
[
828,
24,
1039
]
],
[
[
314,
1,
560
],
[
560,
63... | [
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
... | Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Nalbuphine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that co... |
DB00500 | DB06603 | 24 | 39 | [
"DDInter1831",
"DDInter1387"
] | Tolmetin | Panobinostat | A non-steroidal anti-inflammatory agent (anti-inflammatory agents, NON-steroidal) similar in mode of action to indomethacin. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress... | Major | 2 | [
[
[
24,
25,
39
]
],
[
[
24,
63,
912
],
[
912,
24,
39
]
],
[
[
24,
24,
578
],
[
578,
63,
39
]
],
[
[
24,
23,
1559
],
[
1559,
24,
... | [
[
[
"Tolmetin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Tolmetin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Inte... | Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Tolmetin may cause a moderate interaction that could exacerbate diseases when taken with Ticagre... |
DB05812 | DB06448 | 1,374 | 171 | [
"DDInter8",
"DDInter1087"
] | Abiraterone | Lonafarnib | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Moderate | 1 | [
[
[
1374,
24,
171
]
],
[
[
1374,
63,
254
],
[
254,
24,
171
]
],
[
[
1374,
64,
888
],
[
888,
24,
171
]
],
[
[
1374,
62,
112
],
[
112,
... | [
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
... | Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Abiraterone may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause ... |
DB06168 | DB15035 | 1,531 | 503 | [
"DDInter281",
"DDInter1959"
] | Canakinumab | Zanubrutinib | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
1531,
24,
503
]
],
[
[
1531,
24,
1430
],
[
1430,
24,
503
]
],
[
[
1531,
63,
1683
],
[
1683,
24,
503
]
],
[
[
1531,
24,
39
],
[
39,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
],
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipuleucel-T may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab a... |
DB00313 | DB02546 | 556 | 137 | [
"DDInter1913",
"DDInter1947"
] | Valproic acid | Vorinostat | Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investig... | Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease persists, gets worse, or comes back during or after treatment with other medicines. It is the first in a new clas... | Major | 2 | [
[
[
556,
25,
137
]
],
[
[
556,
6,
1778
],
[
1778,
45,
137
]
],
[
[
556,
6,
17332
],
[
17332,
57,
137
]
],
[
[
556,
21,
28709
],
[
28709,
... | [
[
[
"Valproic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorinostat"
]
],
[
[
"Valproic acid",
"{u} (Compound) binds {v} (Gene)",
"HDAC2"
],
[
"HDAC2",
"{u} (Gene) is bound by {v} (Compound)",
"Vor... | Valproic acid (Compound) binds HDAC2 (Gene) and HDAC2 (Gene) is bound by Vorinostat (Compound)
Valproic acid (Compound) binds ALDH5A1 (Gene) and ALDH5A1 (Gene) is downregulated by Vorinostat (Compound)
Valproic acid (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Vor... |
DB06663 | DB08875 | 1,154 | 1,618 | [
"DDInter1398",
"DDInter262"
] | Pasireotide | Cabozantinib | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Major | 2 | [
[
[
1154,
25,
1618
]
],
[
[
1154,
62,
112
],
[
112,
23,
1618
]
],
[
[
1154,
24,
384
],
[
384,
63,
1618
]
],
[
[
1154,
63,
122
],
[
122,
... | [
[
[
"Pasireotide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Pasireotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metro... | Pasireotide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and ... |
DB00612 | DB06703 | 1,121 | 619 | [
"DDInter216",
"DDInter793"
] | Bisoprolol | Gadobutrol | Bisoprolol is a cardioselective β1-adrenergic blocking agent used to treat high blood pressure.[A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. Bisoprolol is generally well tolerated, likely due to its β1-ad... | Gadobutrol is a second-generation extracellular non-ionic macrocyclic GBCA (gadolinium-based contrast agent) used in magnetic resonance imaging (MRI) in adults and children older than 2 years of age. Due to its physicochemical properties, gadobutrol is formulated at twice the gadolinium ion concentration compared to ot... | Moderate | 1 | [
[
[
1121,
24,
619
]
],
[
[
1121,
21,
29765
],
[
29765,
60,
619
]
],
[
[
1121,
1,
819
],
[
819,
24,
619
]
],
[
[
1121,
24,
1013
],
[
1013,
... | [
[
[
"Bisoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobutrol"
]
],
[
[
"Bisoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Aphasia"
],
[
"Aphasia",
"{u} (Side Effect) is caused b... | Bisoprolol (Compound) causes Aphasia (Side Effect) and Aphasia (Side Effect) is caused by Gadobutrol (Compound)
Bisoprolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Gadobutrol
Bisoprolol may cause a moderate interaction that... |
DB01211 | DB01261 | 609 | 170 | [
"DDInter393",
"DDInter1679"
] | Clarithromycin | Sitagliptin | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
609,
24,
170
]
],
[
[
609,
6,
8374
],
[
8374,
45,
170
]
],
[
[
609,
21,
28850
],
[
28850,
60,
170
]
],
[
[
609,
24,
52
],
[
52,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Clarithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Co... | Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sitagliptin (Compound)
Clarithromycin (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulag... |
DB00911 | DB01432 | 458 | 857 | [
"DDInter1811",
"DDInter368"
] | Tinidazole | Cholestyramine | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Moderate | 1 | [
[
[
458,
24,
857
]
],
[
[
458,
40,
112
],
[
112,
24,
857
]
],
[
[
458,
63,
126
],
[
126,
24,
857
]
],
[
[
458,
24,
1377
],
[
1377,
2... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholestyramine"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause... | Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Cholestyramine
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that... |
DB01359 | DB09481 | 729 | 460 | [
"DDInter1417",
"DDInter1113"
] | Penbutolol | Magnesium carbonate | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Magnesium carbonate, also known as magnesite, is a common over the counter remedy for heartburn and upset stomach caused by overproduction of acid in the stomach [FDA Label]. | Minor | 0 | [
[
[
729,
23,
460
]
],
[
[
729,
63,
401
],
[
401,
23,
460
]
],
[
[
729,
40,
461
],
[
461,
23,
460
]
],
[
[
729,
1,
699
],
[
699,
23,
... | [
[
[
"Penbutolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
]
],
[
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],... | Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Penbutolol (Compound) resembles Timolol (Compound) and Timolol may cause a minor interaction that can... |
DB00773 | DB13007 | 896 | 1,060 | [
"DDInter702",
"DDInter642"
] | Etoposide | Enfortumab vedotin | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitoti... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
896,
24,
1060
]
],
[
[
896,
24,
129
],
[
129,
23,
1060
]
],
[
[
896,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
896,
63,
58
],
[
58,
... | [
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
... | Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib an... |
DB01021 | DB11348 | 674 | 1,065 | [
"DDInter1861",
"DDInter279"
] | Trichlormethiazide | Calcium Phosphate | A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p830) | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
674,
24,
1065
]
],
[
[
674,
1,
1014
],
[
1014,
24,
1065
]
],
[
[
674,
62,
1620
],
[
1620,
24,
1065
]
],
[
[
674,
40,
178
],
[
178,
... | [
[
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Benzthiazide"
],
[
"Benzthiazide",
... | Trichlormethiazide (Compound) resembles Benzthiazide (Compound) and Benzthiazide may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Trichlormethiazide may cause a minor interaction that can limit clinical effects when taken with Tetracycline and Tetracycline may cause a mo... |
DB00987 | DB10343 | 1,224 | 962 | [
"DDInter460",
"DDInter160"
] | Cytarabine | Bacillus calmette-guerin substrain tice live antigen | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Bacillus calmette-guerin substrain tice live antigen is a vaccine containing attenuated live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of *Mycobacterium bovis* for percutaneous use. It is administered to prevent the development of tuberculosis. | Major | 2 | [
[
[
1224,
25,
962
]
],
[
[
1224,
64,
1057
],
[
1057,
25,
962
]
],
[
[
1224,
24,
270
],
[
270,
64,
962
]
],
[
[
1224,
63,
663
],
[
663,
... | [
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bacillus calmette-guerin substrain tice live antigen"
]
],
[
[
"Cytarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
... | Cytarabine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Bacillus calmette-guerin substrain tice live antigen
Cytarabine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizum... |
DB04951 | DB12332 | 187 | 1,619 | [
"DDInter1477",
"DDInter1626"
] | Pirfenidone | Rucaparib | Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is pro... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
187,
25,
1619
]
],
[
[
187,
24,
271
],
[
271,
23,
1619
]
],
[
[
187,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
187,
24,
1362
],
[
1362,
... | [
[
[
"Pirfenidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Pirfenidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirabegron"
],
[
"Mirabegro... | Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Pirfenidone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib ... |
DB01050 | DB01265 | 848 | 1,477 | [
"DDInter900",
"DDInter1757"
] | Ibuprofen | Telbivudine | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. | Moderate | 1 | [
[
[
848,
24,
1477
]
],
[
[
848,
63,
139
],
[
139,
1,
1477
]
],
[
[
848,
21,
28745
],
[
28745,
60,
1477
]
],
[
[
848,
24,
1220
],
[
1220,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine (Compound) resembles Telbivudine (Compound)
Ibuprofen (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Telbivudine (Compound)
Ibuprofen may cause ... |
DB00959 | DB01136 | 1,486 | 772 | [
"DDInter1191",
"DDInter305"
] | Methylprednisolone | Carvedilol | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Carvedilol is a racemic mixture where the S(-) enantiomer is both a beta and alpha-1 adrenoceptor blocker, and the R(+) enantiomer is an alpha-1 adrenoceptor blocker.[L7889,L7892] It is currently used to treat heart failure, left ventricular dysfunction, and hypertension.[L7889,L7892] The dual action of carvedilol is a... | Moderate | 1 | [
[
[
1486,
24,
772
]
],
[
[
1486,
6,
4973
],
[
4973,
45,
772
]
],
[
[
1486,
21,
28734
],
[
28734,
60,
772
]
],
[
[
1486,
23,
1283
],
[
1283... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carvedilol"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v... | Methylprednisolone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Carvedilol (Compound)
Methylprednisolone (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Carvedilol (Compound)
Methylprednisolone may cause a minor interaction that can limit clinic... |
DB00697 | DB06282 | 876 | 516 | [
"DDInter1821",
"DDInter1053"
] | Tizanidine | Levocetirizine | Tizanidine is a fast-acting drug used for the management of muscle spasm, which may result from the effects of multiple sclerosis, stroke, an acquired brain injury, or a spinal cord injury. It may also be caused by musculoskeletal injury. Regardless of the cause, muscle spasticity can be an extremely painful and debili... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
876,
24,
516
]
],
[
[
876,
63,
701
],
[
701,
24,
516
]
],
[
[
876,
24,
407
],
[
407,
63,
516
]
],
[
[
876,
24,
1219
],
[
1219,
2... | [
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Tizanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Tizanidine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium m... |
DB00814 | DB01362 | 1,171 | 497 | [
"DDInter1143",
"DDInter960"
] | Meloxicam | Iohexol | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
1171,
25,
497
]
],
[
[
1171,
25,
258
],
[
258,
40,
497
]
],
[
[
1171,
21,
28681
],
[
28681,
60,
497
]
],
[
[
1171,
24,
891
],
[
891,
... | [
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Meloxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} (Compoun... | Meloxicam may lead to a major life threatening interaction when taken with Iodixanol and Iodixanol (Compound) resembles Iohexol (Compound)
Meloxicam (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Meloxicam may cause a moderate interaction that could e... |
DB00418 | DB06772 | 536 | 310 | [
"DDInter1650",
"DDInter259"
] | Secobarbital | Cabazitaxel | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Cabazitaxel is a taxoid synthesized from 10-deacetylbaccatin III, a compound isolated from the yew tree. As a second-generation semisynthetic microtubule inhibitor, cabazitaxel stabilizes microtubules and induces tumour cell death. Due to its low affinity for the P-glycoprotein (P-gp) efflux pump, cabazitaxel can more ... | Moderate | 1 | [
[
[
536,
24,
310
]
],
[
[
536,
24,
973
],
[
973,
24,
310
]
],
[
[
536,
6,
3486
],
[
3486,
45,
310
]
],
[
[
536,
21,
28766
],
[
28766,
... | [
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
]
],
[
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
... | Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel
Secobarbital (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cabazitaxel (Compound)
Secobarbital... |
DB00283 | DB00754 | 701 | 157 | [
"DDInter395",
"DDInter696"
] | Clemastine | Ethotoin | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Ethotoin is a hydantoin derivative and anticonvulsant. Ethotoin exerts an antiepileptic effect without causing general central nervous system depression. The mechanism of action is probably very similar to that of phenytoin. The latter drug appears to stabilize rather than to raise the normal seizure threshold, and to ... | Moderate | 1 | [
[
[
701,
24,
157
]
],
[
[
701,
24,
759
],
[
759,
40,
157
]
],
[
[
701,
24,
499
],
[
499,
1,
157
]
],
[
[
701,
21,
28921
],
[
28921,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethotoin"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primidone"
],
[
... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Primidone and Primidone (Compound) resembles Ethotoin (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Phensuximide and Phensuximide (Compound) resembles Ethotoin (Compound)
Cl... |
DB00743 | DB00960 | 808 | 887 | [
"DDInter792",
"DDInter1471"
] | Gadobenic acid | Pindolol | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Pindolol is a first generation non-selective beta blocker used in the treatment of hypertension. Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia. Research into pindolol's use in the treatment of hypertension began in the earl... | Moderate | 1 | [
[
[
808,
24,
887
]
],
[
[
808,
63,
726
],
[
726,
1,
887
]
],
[
[
808,
24,
819
],
[
819,
40,
887
]
],
[
[
808,
63,
88
],
[
88,
40,
... | [
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pindolol"
]
],
[
[
"Gadobenic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betaxolol"
],
... | Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Betaxolol and Betaxolol (Compound) resembles Pindolol (Compound)
Gadobenic acid may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol (Compound) resembles Pindolol (Compound... |
DB00726 | DB08868 | 1,164 | 1,011 | [
"DDInter1876",
"DDInter737"
] | Trimipramine | Fingolimod | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
1164,
25,
1011
]
],
[
[
1164,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
1164,
21,
28859
],
[
28859,
60,
1011
]
],
[
[
1164,
23,
112
],
[
... | [
[
[
"Trimipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Trimipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fin... | Trimipramine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Trimipramine (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)
Trimipramine may cause a minor interaction that can limit clinical effects when ... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.